BALTIMORE, Md. — BioIVT, a global research partner and biospecimen solutions provider supporting drug and diagnostic development, announced the acquisition of BeCytes Biotechnologies, a Barcelona, Spain-based company specializing in the coordination, collection, processing, and distribution of high-quality human tissues and cells for biomedical research. The acquisition strengthens BioIVT’s European presence and advances its commitment to supporting New Approach Methodologies (NAMs) and absorption, distribution, metabolism, and excretion (ADME) research areas.
Through this acquisition, BioIVT expands its access to ethically sourced and high-quality biospecimens—particularly primary hepatocytes—offering researchers worldwide enhanced resources for predictive and translational research. BeCytes’ expertise in tissue sourcing and primary cell isolation complements BioIVT’s existing biospecimen and research service portfolio, reinforcing its leadership in advancing NAMs.
“As global demand increases for NAMs and more predictive research models, access to ethically sourced tissues and cells has never been more critical,” said Richard Haigh, CEO of BioIVT. “With this acquisition, we’re expanding our reach, enhancing our portfolio, and giving scientists the high-quality specimens they need to drive innovation and accelerate medical breakthroughs.”
Founded in 2015, BeCytes has become a trusted partner to pharmaceutical, biotechnology, and academic researchers seeking coordinated human tissue procurement and primary cell production. The company is recognized for its innovation in R&D and its ability to produce primary liver cells from both human and animal sources. This strategic acquisition positions BioIVT to meet growing global demand for NAMs and to contribute to the development of next-generation therapies.
“At BeCytes, our vision has always been to accelerate preclinical research to improve patients’ lives by driving innovation and enabling scientific discovery,” said Jordi Xapellí, CEO of BeCytes Biotechnologies. “For years, we have viewed BioIVT as a benchmark of excellence in our industry, with the global reach and expertise to match. This partnership marks an exciting step forward in our shared mission—expanding our capabilities and strengthening our connection with the research community. We are proud to join forces with the world-class team at BioIVT.”
“BeCytes’ expertise in liver cell isolation, together with its strong tissue sourcing network, provides access to one of Europe’s most active regions for preclinical research,” added Christopher Black, Chief Operating Officer of BioIVT. “This ensures that biomaterials and cells used in NAMs and other research services are obtained under the highest ethical and quality standards.”
“Barcelona is consolidating itself as a leading European biotechnology hub, with significant investment driving innovation in preclinical research and therapeutic development,” said Estephan Arredondo, Technical Director of BeCytes.
BeCytes will continue to operate from its Barcelona headquarters. Financial details of the transaction were not disclosed.
